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ABSTRACT:
Introduction: breast cancer is one of the main causes of death among women in Brazil and worldwide.
The diagnosis of breast neoplasms usually represents an emotional burden, and it may lead to
adjustment reactions and even be the trigger for affective disorders (mainly depression), anxiety or
psychosis. The Beck Depression Inventory (BDI) is one of the most used mechanisms for the evaluation
of depression in research and in clinics. Depression prevalence in patients with cancer varies from
3% to 55% among different studies.  Methodological variation, different instruments to assess
depression and different cut-off points for diagnosis contribute to the huge discrepancy in current
findings. In general, the more specifically depression is defined and evaluated, the lower the rates of
prevalence are reported. Many articles fail to demonstrate a statistical significance in the relationship
between depression and cancer-specific factors. This suggests that risk factors for depression in
those patients are more related to the patient   as contextual variables and premorbid factors of
personality – and not to the cancer or its treatment. Objective: to determine the prevalence of
major depression in women with breast cancer. Methods: a cross-sectional study was conducted in
women with breast cancer. The sample consisted of 51 patients who answered the Beck Depression
Inventory (BDI). The presence of depression was considered in cases where the scores were above
20. A questionnaire with additional data about the patients such as age, marital status, ethnicity,
education, family income, family history of depression and breast cancer, and cancer-related variables
including staging, months since diagnosis, treatment modality, type of surgery, alopecia occurring
were used. Descriptive analysis and test of association (chi-square) were conducted. Results: the
prevalence of major depression was 5.9%, similar to that observed in community samples.
Subsyndromal depressive symptoms had a score of 21.6% (BDI scores from 16 to 20). Chi-square
test was conducted and showed no statistically significant relationship between the classification of
BDI and the variables tested (characteristics related to patient and cancer-specific). This indicates
that the isolated context of the variables does not influence the event of depression. Conclusion:
the prevalence of major depression in women with breast neoplasms was 5.9%.
Key words: breast cancer, breast neoplasms, prevalence, cross-sectional studies, major depression,
mood disorders.
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INTRODUCTION
Breast cancer is the second most common
type of cancer in the world population and more
common among women, being one of the leading
causes of death among them worldwide.1–3. About
520,000 deaths from the disease has been
estimated for the year 2012. In Brazil, in 2010, the
number of deaths due to this cancer was 12,852
(12,705 females and 147 males)2 and these
mortality rates remain high in the country because
the disease is still diagnosed in advanced stages.3
Cancer places specific demands on
individuals, with substantial stressors both at
diagnosis and during treatment.4 Mammary
neoplasms make demands on women’s physical and
psychological aspects,5 and within the analysis of
the patients’ surgical and adjuvant treatment the
impact on their mental health should be
emphasized6.
Cancer diagnosis is usually an emotional
overload which can trigger reactions and emotional
adjustment or even be the trigger for affective
disorders (especially depression), anxiety or even
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Clinical application: To screen patients with breast cancer without previous depression diagnosis in
a proper way, avoiding the classification of subsyndromal depressive symptoms or moderate depressive
disorders such as major depression.
Prevalence of major depression in patients with breast cancer Journal of Human Growth and Development, 2015; 25(1): 68-74
– 69 -
psychosis.7 However, it is important to highlight that
not every change in mood can be considered as
depression. Often the patient only has mild
emotional lability or mood changes.
Of all the mood complications linked to cancer,
depression has been the most widely investigated,
but despite many years of research, the prevalence
of depression in cancer patients is still a matter of
much debate.8
The prevalence of depression in patients with
cancer has varied widely in different studies. An
extensive review study, conducted by Spiegel,
reported variations in rates between 4.5% to
50.9%. Other studies have shown ‘a variation of
between 3% to 55% of cases of depression in breast
cancer10-12. These studies generally encompass all
depressive disorders and not just major
depression.5,13,14 A lack of standardization, especially
with regards to methods of assessment,
questionnaire scores to measure depression and
diagnostic criteria contribute to the large
discrepancy between the values. In general, the
more specifically the term ‘depression’ is defined
and evaluated, the lower the prevalence rates
reported, including a meta-analysis published in
2011 in The Lancet, in which the authors identified
an association between low prevalence of
depression and high-quality studies published
recently.8
Although much is talked of the association
between breast cancer and depression, several
studies have failed to show statistical significance
between depression and cancer-related variables.
Risk factors for depression appear to be more
related to the patient rather than to the cancer itself
or its treatment.6,12,15–21 The hypothesis tested in
this study is the prevalence of major depression in
patients with breast cancer is similar to the
community samples of around 5%.7,22–24. A patient’s
psychosocial factors, particularly their social and
premorbid characteristics and inherent personality,
are most often associated with depression in breast
cancer.
Thus, the objective of this study was to
determine the prevalence of major depression in
women with breast cancer.
METHODS
A cross-sectional study of prevalence in Cariri
Oncology Center, located in Barbalha – CE, in north-
eastern Brazil was conducted.
The total sample consisted of 51 women. The
calculation for determining the size of this sample
considered the prevalence of major depressive
disorders as 5% (prevalence in adult women in the
general population7.22–24) absolute precision of 6%
and a  significance level of 5%.
Inclusion criteria were: patients had to be
older than 18, diagnosed with breast cancer and
were receiving anticancer treatment, and had signed
an informed consent form.
Overall, 59 women were screened for the
study, of whom 51 were enrolled in the study. Eight
were excluded (3 because they were not undergoing
treatment and 5 because they refused to participate
in the research).
The occurrence of depression was detected
through the Beck Depression Inventory (BDI).
Statistical analysis was performed using the chi-
square (c2). A questionnaire was also used with the
following additional data: age, demographic and socio
and economic data (marital status, ethnicity,
education, family income), family history of
depression, family history of breast cancer, time since
diagnosis (in months), tumour staging, treatment
performed, type of surgery (mastectomy or
conservative surgery) and the occurrence of alopecia.
The BDI is probably the most used measure
of self-assessment for depression both in research
and in clinics25. Several findings corroborate its
validity in clinical and non-clinical populations. It
has been translated into several languages  ,
including into Portuguese.26 It consists of a
questionnaire containing 21 items, which include
symptoms and attitudes, with an intensity ranging
from 0 to 3 at a high gradation. A score of 0
represents the absence of symptoms or assessed
attitude. A score of 3 equals the presence of
symptoms or more serious attitudes.27,28 The 21
items assessed refer to sadness, pessimism, sense
of failure, lack of satisfaction, guilt, sense of
punishment, self-deprecation, self-accusation,
suicidal ideas, crying spells, irritability, social
withdrawal, indecisiveness, distortion of body
image, work inhibition, sleep disturbance, fatigue,
loss of appetite, weight loss, somatic preoccupation
and decreased libido.
There are several proposed cut-off points to
distinguish levels of depression using the BDI. The
Center of Cognitive Therapy recommends the
following cut-off points for samples of patients with
affective disorder: <10 = no or minimal depression;
10–18 = mild to moderate depression; 19–29 =
moderate to severe depression; 30–63 = grave
depression.29 Different guidelines recommend, for
samples not diagnosed, that scores above 15 detect
‘dysphoria’ (defined by the authors as a ‘non-specific
negative affectivity’). They concluded that, because
it refers to more severe cases, the term ‘depression’
should only be used for individuals with scores above
20.28,30 In updating these designations, dysphoria
was classified in our study as subsyndromal
depressive symptoms (SDS) and severe or grave
depression were changed to major depression.
 The standard cut-off points for this study
were < 15 = no depression, 16–20 = subsyndromal
depressive symptoms, > 20 = major depression.
RESULTS
Among the 51 women with breast cancer, the
prevalence of major depression was 5.9% (Table 1).
Only three patients had a BDI score of > 20. This
prevalence rate was therefore similar to that found
in the general female population.
Of the patients, 21.6% had subsyndromal
depressive symptoms and 72.5% (Table 1) were
classified, according to BDI, as having no change
(score < 15).
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Table 2 shows general data related to the
51 patients studied. An average age of 58.5 ±
14.2 years old was verified, with values between
26 (minimum age) and 86 (maximum age), 70.6%
of them were between the ages of 40 and 69
years. Of those surveyed, 58.8% were married
and 64.7% were white (ethnic categorization
followed the classification of the Brazilian Institute
of Geography and Statistics, which considers skin
colour). With regards to education, 82.4% had
not completed high school and only 9.8% had a
college degree. With respect to family income
(based on the Brazilian minimum wage which
corresponds to US$ 289.58 per month), 86.3%
had an income of up to US$ 579.17 per month. A
total of 9.8% patients had a family history of
breast  cancer and 13.7% had a family history of
depression.
Table 1: Distribution of 51 women with breast cancer, classified according to the Beck Depression Inventory.
Barbalha-CE, Brazil, in 2014
BDI Score N %
No alteration 37 72,5
SDS 11 21,6
Depression 3 5,9
Total 51 100
Abbreviations: BDI, Beck’s Depression Inventory; SDS, Subsyndromal Depressive Symptoms.
Table 2: Characteristics related to 51 women with breast cancer, distributed according to the classification
of the Beck Depression Inventory (BDI), then c2 test. Barbalha-CE, Brazil, in 2014
         No alteration           SDS            Depression                    χ2
Variables Total (%) N % N % N % χ2 P
Age (in years)
< 40 5 (9,8) 3 8,1 1 9,1 1 33,3 2,918 0,232
40 to 59 18 (35,3) 17 46,0 1 9,1 0 -
60 to 69 18 (35,3) 12 32,4 4 36,4 2 66,7
> 70 10 (19,6) 5 13,5 5 45,4 0 -
Total 51 (100) 37 100 11 100 3 100
Marital Status
Married 30 (58,8) 22 59,5 5 45,4 3 100 3,399 0,493
Widow 11 (21,6) 7 18,9 4 36,4 0 -
Single 8 (15,7) 6 16,2 2 18,2 0 -
Divorced 2 (3,9) 2 5,4 0 - 0 -
Total
Ethnicity 51 (100) 37 100 11 100 3 100
White 33 (64,7) 26 70,3 5 45,4 2 66,7 4,363 0,628
Brown 11 (21,6) 7 18,9 3 27,3 1 33,3
Black 7 (13,7) 4 10,8 3 27,3 0 -
Total 51 (100) 37 100 11 100 3 100
Education
< High School 42 (82,4%) 30 81,1 10 90,9 2 66,7 2,098 0,350
Completed High School 4 (7,8%) 3 8,1 0 - 1 33,3
College Graduate 5 (9,8%) 4 10,8 1 9,1 0 -
Total 51 (100%) 37 100 11 100 3 100
Family Monthly Income (US$)
< 289,58 23 (45,1%) 18 48,7 5 45,5 0 - 2,098 0,911
> 289,58 and < 579,17 21 (41,2%) 13 35,1 5 45,5 3 100
> 579,17 7 (13,7%) 6 16,2 1 9 0 -
Total 51 (100%) 37 100 11 100 3 100
Family History of  depression
No 44 31 83,8 11 100 2 66,7 12,159 0,059
Yes 7 6 16,2 0 - 1 33,3
Total 51 37 100 11 100 3 100
Family History of Breast Cancer
No 46 32 86,5 11 100 3 100 11,593 0,313
Yes 5 5 13,5 0 - 0 -
Total 51 37 100 11 100 3 100
Abbreviations: SDS, Subsyndromal Depressive Symptoms; US$, American Dollars.
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Data related to breast cancer showed that
39.2% of patients had been diagnosed within the
last 12 months, 70.6% were in a period of 36
months since their cancer diagnosis; 41.2% were
at tumour stage IIA. Regarding the type of
treatment, 92.1% had surgery, with 58.8% having
undergone mastectomy; 37.3% of patients were
treated with surgery and chemotherapy, and 35.3%
had surgery combined with chemotherapy and
radiotherapy. had Alopecia, resulting from the use
of chemotherapy, affected 74.5%
From the application of the chi-square test,
there were no statistically significant differences
(p < 0.05) in the classification of the BDI due to
the variables tested, as shown in tables 2 and 3.
This occurred both in characteristics related to the
patients themselves (age, marital status, ethnicity,
education, family income, family history of
depression, family history of breast cancer) and
those related to breast cancer and its treatment
(time since diagnosis, tumour stage, type of
treatment, type of surgery and alopecia), indicating
that the isolated context of the variables does not
influence the event of depression. The only variable
that showed a trend towards statistical significance
(p = 0.059) was a family history of depression.
DISCUSSION
The prevalence of major depression among
women with breast cancer found in this study was
similar to rates reported in studies of women in the
general population geral.7,22–24
Most of the patients studied showed no
significant changes in mood, according to the
classification from the scores of the Beck Depression
Inventory (BDI). Although the diagnosis of breast
cancer impacts on several areas of the patient’s
life, triggering mood swings, it was noticed that
some women expressed subsyndromal depressive
symptoms, but the vast majority did not have major
depression (clinically significant depressive
symptoms).
The diagnosis of cancer is an emotional
overload; however, the onset of depression appears
to be more related to the inherent characteristics
of the patient (patient’s personality and
comorbidities pre-cancer) than to the characteristics
related to cancer and its treatment.6,12,15,16
The variables studied in this article were
selected from what the literature refers to as factors
related to breast cancer and major depression. The
results found support for the initial hypothesis,
Table 3: Characteristics related to breast cancer and its treatment in 51 women, distributed according to
the classification of the Beck Depression Inventory (BDI), then χ2 test. Barbalha-CE, Brazil, in 2014
             No alteration               SDS              Depression                   χ2
Variables Total (%) N % N % N % χ2 P
Time of diagnosis (in months)
< 12 20 (39,2) 16 43,2 2 18,2 2 66,7 0,788 0,674
From 12 to 36 16 (31,4) 10 27,1 5 45,4 1 33,3
> 36 15 (29,4) 11 29,7 4 36,4 0 -
Total 51 (100) 37 100 11 100 3 100
Staging
IIA 21 (41,2) 15 40,5 5 45,4 1 33,3 7,622 0,471
IIB 8 (15,7) 7 19,0 1 9,1 0 -
IIIA 7 (13,7) 4 10,8 2 18,2 1 33,3
IIIB 14 (27,4) 11 29,7 2 18,2 1 33,3
IV 1 (2,0) 0 - 1 9,1 0 -
Total 51 (100) 37 100 11 100 3 100*
Type of treatment
CIR+ QT 19 (37,3) 11 29,7 6 54,5 2 66,7 6,436 0,598
CIR+ QT+ RT 18 (35,3) 14 37,9 4 36,4 0 -
CIR+QT+RT+HT 6 (11,8) 5 13,5 0 - 1 33,3
CIR+QT+QT 4 (7,8) 4 10,8 0 - 0 -
QT only 4 (7,8) 3 8,1 1 9,1 0 -
Total 51 (100) 37 100 11 100 3 100
Type of surgery
Mastectomy 30 22 59,5 6  54,5 2 66,7 0,368 0,985
Quadrantectomy 17 12 32,4 4 36,4 1 33,3
No  surgery 4 3 8,1 1 9,1 0 -
Total 51 37 100 11 100 3 100
Occurrence of alopecia
Yes 38 28 75,7 7 63,6 3 100 3,116 0,211
No 13 9 24,3 4 36,4 0 -
Total 51 37 100 11 100 3 100
Abbreviations: SDS, Subsyndromal Depressive Symptoms; CIR, Surgery; QT, Chemotherapy; RT, Radiotherapy; HT,
Hormonetherapy. * The total was approximately 100.
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which admitted that the prevalence of major
depression among women with breast cancer is
similar to point prevalence found in community
samples.
As in other studies, there was no statistically
significant association of cancer-specific variables
with depression,12,15–19,21  indicating that these
variables alone did not have an influence on
depression. The only variable with a trend toward
statistical significance was a family history of
depression ( p = 0.059 ) and it is known that major
depressive disorder is 1.5 to 3 times more common
among first-degree biological relatives of people
with this disorder than among the general
population.7
Breast cancer is an unpleasant event that can
bring traumatic experiences to the patient, such as
fear of death, altered self-image, uncertainty as to
treatment and prognosis. After receiving the
diagnosis, many women face personal conflicts,
some have difficulty in accepting the disease, seem
afraid of suffering social discrimination or even
discrimination within the family, in addition to facing
feelings of mutilation resulting from complete or
partial removal of the breast, the part of the body
directly connected to the representation of her
femininity. All these changes from the occurrence
of cancer can be reflected as disturbances in mood,
self-esteem and sexuality .
It is important to note, however, that all these
changes caused by breast cancer in the context of
the biopsychosocial woman do not necessarily lead
to the onset of major depression – the patient may
manifest milder affective disorders, adjustment
reactions or subsyndromal depressive symptoms.
It is assumed that functional, everyday stress and
other disorders unrelated to cancer cause major
influence on the patient’s psychological function,
due to factors inherent in the premorbid
personality.16 Contextual variables, rather than risk
factors directly related to cancer, appear to be
predictive factors for the onset of depression in
breast cancer patients12,15–17, among which stand out
the structure of personality and problem-coping
ability.6
The majority of our sample consisted of
women older than 49 years old, white, married, of
low education, low income, no family history of
breast cancer and / or depression. With respect to
breast cancer, most of them were within 36 months
of diagnosis, had advanced staging, had surgery
associated with other treatment modalities
(chemotherapy, radiotherapy and / or hormone
therapy), underwent total removal of the breast
(mastectomy) and also had alopecia due to
chemotherapy.
After applying the chi-square test, it was
found that age, marital status, and socio-economic
status of patients (education and income) were not
related to the depression event, nor to family history
of breast cancer and depression.
It has been found that a shorter time since
the diagnosis of cancer, the severity of the disease
(late stages), the type of treatment (surgery,
chemotherapy, radiation therapy and / or hormone
therapy), as well as the type of surgery (removal
or preservation of the breast) showed no correlation
with major depression. This was also the case with
respect to alopecia.
There is no consensus in the literature
regarding the findings of association of variables
related to cancer with depressive disorders. Some
data suggest that the onset of mood disorders may
vary according to the stage of cancer treatment,20,31
staging32 or type of treatment33,34  while others found
no cancer-specific influence.12,15,16
Breast cancer and depression are public
health problems. When a community or population
has a problem. the first step is to ask the question,
what is the problem then to decide what works and
decide on an intervention or a program35. Prevalence
studies help in this first step it is important for public
health decisions.
As can be seen in Table 1, it was considered
that women with high scores (above 20) in BDI have
major depression (clinically significant depressive
symptoms). However, because it is a cross-sectional
study, data regarding causality could not be
determined.
The literature presents studies with very
disparate prevalence rates of depression among
breast cancer patients.5,8–10,13,14 However, these
studies refer not only to depression, but include all
types of depressive disorders. Major depression
should not be confused with a simple sense of
sadness, with transient changes in mood or mild
depressive symptoms – to do so risks
overestimating its prevalence; it is critical to assess
patients carefully for the presence of depressive
symptoms.
Thus, the more specifically the term
depression is defined and evaluated, the lower the
prevalence rates found in the literature, including
the association between depression and ‘the low
prevalence of currently published high-quality
scientific studies8.
In summary, the prevalence of major
depression in women with breast cancer was 5.9%.
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RESUMO:
Introdução: o câncer de mama é uma das principais causas de morte entre as mulheres no Brasil
e no mundo. O diagnóstico de neoplasia mamária geralmente representa uma sobrecarga emocional,
podendo desencadear reações de ajustamento ou mesmo ser gatilho de quadros afetivos
(principalmente depressão), ansiedade ou até mesmo psicoses. O Inventário de Depressão de Beck
(IDB) é um dos instrumentos mais usados para avaliação de depressão, tanto em pesquisa quanto
em clínica. A prevalência de depressão em pacientes com câncer tem variado bastante em diferentes
trabalhos, de 3 a 55%. A falta de padronização, especialmente no que diz respeito aos métodos de
avaliação, escore/ponto de corte, tipo de entrevista e critérios para diagnóstico contribuem para a
grande discrepância nos achados desses estudos. No geral, quanto mais especificamente o termo
depressão é definido e avaliado, menores índices de prevalência são reportados. Vários trabalhos
falharam em mostrar significância estatística entre depressão e variáveis relacionadas ao câncer,
sugerindo que os fatores de risco para depressão parecem estar mais relacionados à própria paciente,
como variáveis contextuais e fatores pré-mórbidos inerentes à sua personalidade, do que ao câncer
em si ou ao seu tratamento. Objetivo: determinar a prevalência de depressão maior em mulheres
com câncer de mama. Método: foi realizado um estudo transversal de prevalência em mulheres
com câncer de mama. A amostra foi constituída por 51 pacientes que responderam o Inventário de
Depressão de Beck (IDB). Considerou-se como presença de depressão os escores maiores do que
20. Foi aplicado também um questionário contendo dados complementares referentes às pacientes
(idade, estado civil, etnia, escolaridade, renda familiar mensal, história familiar de depressão e de
câncer de mama) e ao câncer (tempo de diagnóstico, estadiamento, tipo de tratamento, ocorrência
de alopécia). Foi realizada análise descritiva e teste de associação (qui-quadrado). Resultados: a
prevalência de depressão maior encontrada foi de 5,9%, semelhante à observada na população
feminina não portadora de câncer de mama. 21,6% apresentaram sintomas depressivos
subsindrômicos (escores do IDB de 16 a 20). A partir do teste de qui-quadrado, não foram observadas
diferenças estatisticamente significativas (p < 0,05) na classificação do IDB em função das variáveis
testadas (características referentes às pacientes e ao câncer em si), indicando que o contexto isolado
das variáveis não exerce influência sobre o evento depressão. Conclusão: mulheres com câncer de
mama apresentaram prevalência de depressão maior de 5,9%.
Palavras-chave: câncer de mama, neoplasia de mama, prevalência, estudos transversais, depressão
maior, transtorno de humor.
